The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00432-022-04247-z.pdf
Reference97 articles.
1. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A (2016) First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol 34(34):4142–4150. https://doi.org/10.1200/jco.2015.65.3949
2. Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS (2018) Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Oncotarget. https://doi.org/10.18632/oncotarget.26239
3. Aladhraei M, Kassem Al-Thobhani A, Poungvarin N, Suwannalert P (2019) Association of XPO1 Overexpression with NF-κB and Ki67 in colorectal cancer. Asian Pac J Cancer Prev 20(12):3747–3754. https://doi.org/10.31557/apjcp.2019.20.12.3747
4. Alzahrani A, Natarajan U, Rathinavelu A (2022) Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells. Cancer Genet 266–267:57–68. https://doi.org/10.1016/j.cancergen.2022.06.003
5. Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F (2017) Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res 19(1):93. https://doi.org/10.1186/s13058-017-0878-6
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Selinexor targets expression of metabolic genes in Merkel cell carcinoma cells;2023-10-10
2. KPNB1-mediated nuclear import in cancer;European Journal of Pharmacology;2023-09
3. Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer;Cancer Research Communications;2023-06-01
4. Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells;Experimental and Therapeutic Medicine;2023-05-16
5. Comprehensive bioinformatics analysis on exportins in lung adenocarcinoma and lung squamous cell carcinoma;Journal of Thoracic Disease;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3